Muscle Mass Versus Body Mass Index As Predictor of Adverse Outcome
Overview
Authors
Affiliations
Groothof D, Shehab N, Erler N, Post A, Kremer D, Polinder-Bos H J Cachexia Sarcopenia Muscle. 2024; 15(4):1528-1538.
PMID: 38898741 PMC: 11294032. DOI: 10.1002/jcsm.13511.
Jo K, Kim K, Lee H, Im J, Kim J, Koh S Intest Res. 2024; 22(4):453-463.
PMID: 38772863 PMC: 11534449. DOI: 10.5217/ir.2024.00044.
Zhou B, Zhang Y, Hiesmayr M, Gao X, Huang Y, Liu S Nutrients. 2024; 16(4).
PMID: 38398893 PMC: 10893253. DOI: 10.3390/nu16040569.
Ertugliflozin, renoprotection and potential confounding by muscle wasting.
Groothof D, Post A, Gans R, Bakker S Diabetologia. 2021; 65(5):906-907.
PMID: 34940888 DOI: 10.1007/s00125-021-05614-0.
Muscle mass versus body mass index as predictor of adverse outcome.
Groothof D, Post A, Polinder-Bos H, Hazenberg B, Gans R, Bakker S J Cachexia Sarcopenia Muscle. 2021; 12(2):517-518.
PMID: 33583115 PMC: 8061409. DOI: 10.1002/jcsm.12686.